Figure 4. Volcano plot of the area under the satraplatin dose–response curve (AUC) by gene signature at the mutation level. More and less sensitive groups of hematopoietic and lymphoid cancer cell lines were defined by considering the difference in AUC between those with gene deletion and those with wild-type gene. Gene deletions conferring enhanced satraplatin sensitivity are depicted on the left [adaptor-related protein complex 4 subunit epsilon 1 (AP4E1), amine oxidase copper-containing 1 (AOC1), B-cell lymphoma 2 (BCL2), BOC cell adhesion-associated oncogene-regulated (BOC), BRCA2 DNA repair-associated (BRCA2), crystallin beta-gamma domain-containing 3 (CRYBG3), DEAD-box helicase 3 X-linked (DDX3X), ethanolamine kinase 2 (ETNK2), FSHD region gene 1 family member B (FRG1B), IQ motif-containing N (KIAA1683), schlafen family member 5 (SLFN5), ubiquitin-specific peptidase 22 (USP22)], and those conferring resistance on the right [EPH receptor A8 (EPHA8), leucine-rich repeat-containing 61 (LRRC6), mitotic spindle-positioning (MISP), phospholipase D1 (PLD1), pregnancy-specific beta-1-glycoprotein 9 (PSG9), SNF2-related CREBBP activator protein (SRCAP) and taste 1 receptor member 2 (TAS1R2)]. Genes achieving statistical significance are marked as black squares (sensitive) and black triangles (resistant).